Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions.

Neurotherapeutics · 2025 · PMC12047478 · PMID 40118715

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

There were nominally significant increases in CSF Aβ 1-42 and Aβ 42/40 ratio in CSF and plasma respectively.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.